Residual or recurrent grade 2 IDH mutant glioma

Clinical trials for Residual or recurrent grade 2 IDH mutant glioma explained in plain language.

Never miss a new study

Get alerted when new Residual or recurrent grade 2 IDH mutant glioma trials appear

Sign up with your email to follow new studies for Residual or recurrent grade 2 IDH mutant glioma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New hope for asian brain tumor patients: targeted pill slows cancer growth

Disease control Ongoing

This study tests an experimental pill, vorasidenib, in Asian patients with a slow-growing but serious brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). About 57 participants will receive either the drug or a placebo to see if it delays tumor progre…

Matched conditions: RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA

Phase 3 • Sponsor: Servier • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

Residual or recurrent grade 2 IDH mutant glioma

Get alerted when new Residual or recurrent grade 2 IDH mutant glioma trials appear

New hope for asian brain tumor patients: targeted pill slows cancer growth